Department of Information Engineering, University of Padova, Padova, Italy.
Department of Surgery, Viborg General Hospital, Denmark.
J Diabetes Res. 2023 Nov 14;2023:7127426. doi: 10.1155/2023/7127426. eCollection 2023.
-cell dysfunction and insulin resistance are the main mechanisms causing glucose intolerance in type 2 diabetes (T2D). Bariatric surgeries, i.e., sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), are procedures both known to induce weight loss, increase insulin action, and enhance -cell function, but hepatic insulin extraction and glucose effectiveness may also play a role.
To determine the contribution of these regulators on glucose tolerance after bariatric surgery, an oral glucose tolerance test (OGTT) was performed before and 2 months after surgery in 9 RYGB and 7 SG subjects. Eight healthy subjects served as metabolic controls. Plasma glucose, insulin, C-peptide, GLP-1, and GIP were measured during each OGTT. Insulin sensitivity and secretion, glucose effectiveness, and glucose rate of appearance were determined via oral minimal models.
RYGB and SG resulted in similar weight reductions (13%, RYGB ( < 0.01); 14%, SG ( < 0.05)). Two months after surgery, insulin secretion ( < 0.05) and glucose effectiveness both improved equally in the two groups (11%, RYGB ( < 0.01); 8%, SG ( > 0.05)), whereas insulin sensitivity remained virtually unaltered. Bariatric surgery resulted in a comparable increase in the GLP-1 response during the OGTT, whereas GIP concentrations remained unaltered. Following surgery, oral glucose intake resulted in a comparable increase in hepatic insulin extraction, the response in both RYGB and SG patients significantly exceeding the response observed in the control subjects.
These results demonstrate that the early improvement in glucose tolerance in obese T2D after RYGB and SG surgeries is attributable mainly to increased insulin secretion and glucose effectiveness, while insulin sensitivity seems to play only a minor role. This trial is registered with NCT02713555.
-细胞功能障碍和胰岛素抵抗是导致 2 型糖尿病(T2D)葡萄糖耐量受损的主要机制。减重手术,即袖状胃切除术(SG)和 Roux-en-Y 胃旁路术(RYGB),均已知可引起体重减轻、增加胰岛素作用和增强 -细胞功能,但肝胰岛素提取和葡萄糖效应也可能发挥作用。
为了确定这些调节剂对减重手术后葡萄糖耐量的贡献,对 9 例 RYGB 和 7 例 SG 患者进行了手术前和手术后 2 个月的口服葡萄糖耐量试验(OGTT)。8 例健康受试者作为代谢对照。在每次 OGTT 期间测量血浆葡萄糖、胰岛素、C 肽、GLP-1 和 GIP。通过口服最小模型确定胰岛素敏感性和分泌、葡萄糖效应和葡萄糖出现率。
RYGB 和 SG 导致相似的体重减轻(13%,RYGB(<0.01);14%,SG(<0.05))。手术后 2 个月,两组胰岛素分泌均同等改善(<0.05),葡萄糖效应也同样改善(11%,RYGB(<0.01);8%,SG(>0.05)),而胰岛素敏感性几乎没有变化。减重手术导致 OGTT 期间 GLP-1 反应的可比增加,而 GIP 浓度保持不变。手术后,口服葡萄糖摄入导致肝胰岛素提取的可比增加,RYGB 和 SG 患者的反应明显超过对照组。
这些结果表明,RYGB 和 SG 手术后肥胖 2 型糖尿病患者葡萄糖耐量的早期改善主要归因于胰岛素分泌和葡萄糖效应的增加,而胰岛素敏感性似乎只起次要作用。这项试验在 NCT02713555 注册。